Soleno Therapeutics Competitors

Edap Tms (NASDAQ:EDAP) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Institutional and Insider Ownership

55.4% of Soleno Therapeutics shares are owned by institutional investors. 74.9% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares Edap Tms and Soleno Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Edap Tms has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Edap Tms and Soleno Therapeutics, as provided by MarketBeat.com.

Edap Tms presently has a consensus target price of $12.50, suggesting a potential upside of 37.67%. Soleno Therapeutics has a consensus target price of $8.6667, suggesting a potential upside of 653.62%. Given Soleno Therapeutics' higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Edap Tms.

Profitability

This table compares Edap Tms and Soleno Therapeutics' net margins, return on equity and return on assets.

Summary

Edap Tms beats Soleno Therapeutics on 6 of the 11 factors compared between the two stocks.

Soleno Therapeutics (NASDAQ:SLNO) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Insider & Institutional Ownership

55.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Second Sight Medical Products shares are held by institutional investors. 74.9% of Soleno Therapeutics shares are held by company insiders. Comparatively, 67.5% of Second Sight Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Soleno Therapeutics and Second Sight Medical Products, as provided by MarketBeat.com.

Soleno Therapeutics presently has a consensus target price of $8.6667, suggesting a potential upside of 653.62%. Given Soleno Therapeutics' higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Second Sight Medical Products.

Valuation & Earnings

This table compares Soleno Therapeutics and Second Sight Medical Products' top-line revenue, earnings per share (EPS) and valuation.

Soleno Therapeutics has higher earnings, but lower revenue than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Soleno Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.

Profitability

This table compares Soleno Therapeutics and Second Sight Medical Products' net margins, return on equity and return on assets.

Summary

Soleno Therapeutics beats Second Sight Medical Products on 9 of the 11 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by insiders. Comparatively, 74.9% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioSig Technologies and Soleno Therapeutics, as reported by MarketBeat.

Soleno Therapeutics has a consensus target price of $8.6667, suggesting a potential upside of 653.62%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than BioSig Technologies.

Profitability

This table compares BioSig Technologies and Soleno Therapeutics' net margins, return on equity and return on assets.

Risk & Volatility

BioSig Technologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioSig Technologies and Soleno Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

Soleno Therapeutics beats BioSig Technologies on 7 of the 8 factors compared between the two stocks.

Soleno Therapeutics (NASDAQ:SLNO) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Risk and Volatility

Soleno Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Insider & Institutional Ownership

55.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 62.1% of FONAR shares are owned by institutional investors. 74.9% of Soleno Therapeutics shares are owned by insiders. Comparatively, 8.6% of FONAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Soleno Therapeutics and FONAR's gross revenue, earnings per share (EPS) and valuation.

FONAR has higher revenue and earnings than Soleno Therapeutics.

Analyst Ratings

This is a breakdown of current ratings for Soleno Therapeutics and FONAR, as reported by MarketBeat.

Soleno Therapeutics presently has a consensus price target of $8.6667, indicating a potential upside of 653.62%. Given Soleno Therapeutics' higher probable upside, equities analysts plainly believe Soleno Therapeutics is more favorable than FONAR.

Profitability

This table compares Soleno Therapeutics and FONAR's net margins, return on equity and return on assets.

Summary

FONAR beats Soleno Therapeutics on 8 of the 11 factors compared between the two stocks.

IRIDEX (NASDAQ:IRIX) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for IRIDEX and Soleno Therapeutics, as provided by MarketBeat.

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Soleno Therapeutics has a consensus target price of $8.6667, indicating a potential upside of 653.62%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than IRIDEX.

Earnings & Valuation

This table compares IRIDEX and Soleno Therapeutics' gross revenue, earnings per share and valuation.

IRIDEX has higher revenue and earnings than Soleno Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IRIDEX has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

32.6% of IRIDEX shares are owned by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are owned by institutional investors. 2.0% of IRIDEX shares are owned by company insiders. Comparatively, 74.9% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IRIDEX and Soleno Therapeutics' net margins, return on equity and return on assets.

Soleno Therapeutics (NASDAQ:SLNO) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Soleno Therapeutics and ENDRA Life Sciences, as provided by MarketBeat.

Soleno Therapeutics presently has a consensus target price of $8.6667, indicating a potential upside of 653.62%. Given Soleno Therapeutics' higher possible upside, equities research analysts clearly believe Soleno Therapeutics is more favorable than ENDRA Life Sciences.

Insider and Institutional Ownership

55.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are held by institutional investors. 74.9% of Soleno Therapeutics shares are held by company insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Soleno Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares Soleno Therapeutics and ENDRA Life Sciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Soleno Therapeutics and ENDRA Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

ENDRA Life Sciences has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Soleno Therapeutics beats ENDRA Life Sciences on 7 of the 11 factors compared between the two stocks.